-
1.发明公开NOVEL 2-AZETIDINONE DERIVATIVES AND THEIR USE AS CHOLESTEROL ABSORPTION INHIBITORS FOR THE TREATMENT OF HYPERLIPIDAEMIA 审中-公开NEW -2-氮杂环丁酮衍生物及其作为胆固醇吸收抑制剂用于治疗高脂血症的用途
公开(公告)号：EP1896407A1
公开(公告)日：2008-03-12
申请号：EP06747933.7
申请日：2006-06-19
申请人： AstraZeneca AB
发明人： ALENFALK, Susanne , DAHLSTRÖM, Mikael , HUNEGNAW, Fana , KARLSSON, Staffan , LEMURELL, Malin , LINDQVIST, Ann-Margret , SKJÄRET, Tore , STARKE, Ingemar
IPC分类号： C07D205/08 , A61K31/397 , A61P3/06
CPC分类号： C07D205/08 , C07K5/06026
摘要： Compounds of formula (I) (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.
-
2.发明公开DIPHENYLAZETIDINONE DERIVATES PROCESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY 审中-公开与胆固醇吸收锁效果DIPHENYLAZETIDINONDERIVATE
公开(公告)号：EP1699758A1
公开(公告)日：2006-09-13
申请号：EP04809132.6
申请日：2004-12-21
申请人： AstraZeneca AB
发明人： ALENFALK, Susanne , DAHLSTRÖM, Mikael , HUNEGNAW, Fana , KARLSSON, Staffan , LEMURELL, Malin , LINDQVIST, Ann-Margret , SKJÄRET, Tore , STARKE, Ingemar
IPC分类号： C07D205/08 , A61K31/397 , A61P3/06 , A61P9/10 , A61P25/28
CPC分类号： C07D205/08
摘要： Compounds of formula (XV): [Chemical formula should be inserted here. Please see paper copy] (XV) (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.
-
3.发明授权
公开(公告)号：EP1173205B1
公开(公告)日：2005-06-01
申请号：EP00928046.2
申请日：2000-04-19
申请人： AstraZeneca AB
CPC分类号： A61K45/06 , A61K9/5026 , A61K9/5047 , A61K9/5078 , A61K31/00 , A61K31/554
摘要： An oral pharmaceutical formulation comprising an inhibitor compound of the ileal bile acid transport (IBAT inhibitor compound) and a therapeutically acceptable carrier characterised in that the formulation is designed to deliver the IBAT inhibitor compound in the ileum. The IBAT inhibitor compound can also be administered in combination with a bile acid binder to alleviate possible side effects of therapy with IBAT inhibitor compound, such as for instance diarrhoea. The bile acid binder may be formulated for colon release.
-
4.发明公开DIPHENYLAZETIDINONE DERIVATIVES FOR TREATING DISORDERS OF THE LIPID METABOLISM 审中-公开Diphenylazetidinone衍生物为血脂异常代谢的治疗
公开(公告)号：EP1521742A1
公开(公告)日：2005-04-13
申请号：EP03762763.5
申请日：2003-07-01
申请人： AstraZeneca AB
发明人： STARKE, Ingemar , DAHLSTROM, Mikael, Ulf, Johan , LINDQVIST, Ann-Margret , NORDBERG, Mats, Peter , SKJARET, Tore , LEMURELL, Malin, Anita
IPC分类号： C07D205/08 , C07D409/12 , A61K31/397 , A61P3/06 , A61P9/10
CPC分类号： C07D409/12 , C07D205/08
摘要： Compounds of formula (I): (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.
-
5.发明公开USE OF BENZOTHIAZEPINES HAVING ACTIVITY AS INHIBITORS OF ILEAL BILE ACID TRANSPORT FOR REDUCING CHOLESTEROLOLEMIA 审中-公开苯并硫氮使用有效的回肠胆汁酸转运抑制剂的用于降低胆固醇血症
公开(公告)号：EP1478368A1
公开(公告)日：2004-11-24
申请号：EP03731763.3
申请日：2003-01-23
申请人： Astrazeneca AB
IPC分类号： A61K31/55
CPC分类号： A61K31/554 , A61K31/00
摘要： The use of an ileal bile acid transport (IBAT) inhibitor and the use of a combination of an IBAT inhibitor and an HMG CoA reductase inhibitor in the treatment of a warm-blooded animal, such as man, with hypercholesterolemia and/or other forms of dyslipidaemia wherein said hypercholesterolemia and dyslipidaemias are characterized by defects in lipoproteins or their receptors is described.
-
6.发明公开ORAL FORMULATION COMPRISING AN INHIBITOR COMPOUND OF THE ILEAL BILE TRANSPORT AND AN HMG CO-A REDUCTASE INHIBITOR 审中-公开口服制剂含回肠胆汁酸转运和一抑制剂的一个HMG Co-A还原酶抑制剂
公开(公告)号：EP1351692A1
公开(公告)日：2003-10-15
申请号：EP01974487.9
申请日：2001-10-12
申请人： AstraZeneca AB
IPC分类号： A61K31/505 , A61P3/06 , A61K31/40
CPC分类号： A61K45/06 , A61K9/143 , A61K9/5026 , A61K9/5036 , A61K9/5078 , A61K31/00
摘要： An oral pharmaceutical formulation comprising an inhibitor compound of the ileal bile acid transport (IBAT inhibitor), an HMG Co-A reductase inhibitor and a therapeutically acceptable carrier characterised in that the formulation is designed to deliver the IBAT inhibitor in the ileum and the HBG Co A reducetase inhibitor non-specifically into the GI tract. The IBAT inhibitor compound and the HMG Co-A reductase inhibitor can also be administered in combination with a bile acid binder to alleviate possible side effects of therapy with IBAT inhibitor compounds, such as for instance diarrhoea. The bile acid binder may be formulated for colon release.
-
7.发明授权DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY 有权与胆固醇吸收锁效果DIPHENYLAZETIDINONDERIVATE
公开(公告)号：EP1699759B1
公开(公告)日：2010-10-20
申请号：EP04809133.4
申请日：2004-12-21
申请人： AstraZeneca AB
发明人： ALENFALK, Susanne , DAHLSTRÖM, Mikael , HUNEGNAW, Fana , KARLSSON, Staffan , LEMURELL, Malin , LINDQVIST, Ann-Margret , SKJÄRET, Tore , STARKE, Ingemar
IPC分类号： C07D205/08 , A61K31/397 , A61P3/06 , A61P9/10 , A61P25/28
CPC分类号： C07D205/08 , A61K38/00 , C07K5/06026 , C07K5/06078
摘要： Compounds of formula (I) (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.
-
8.发明公开DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY 有权二苯并二氮杂酮衍生物具有胆固醇吸收抑制活性
公开(公告)号：EP1699759A1
公开(公告)日：2006-09-13
申请号：EP04809133.4
申请日：2004-12-21
申请人： AstraZeneca AB
发明人： ALENFALK, Susanne , DAHLSTRÖM, Mikael , HUNEGNAW, Fana , KARLSSON, Staffan , LEMURELL, Malin , LINDQVIST, Ann-Margret , SKJÄRET, Tore , STARKE, Ingemar
IPC分类号： C07D205/08 , A61K31/397 , A61P3/06 , A61P9/10 , A61P25/28
CPC分类号： C07D205/08 , A61K38/00 , C07K5/06026 , C07K5/06078
摘要： Compounds of formula (I) (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.
摘要翻译： 描述了式（I）化合物（其中可变基团如上定义）药学上可接受的盐，溶剂化物，这些盐的溶剂化物和前药以及它们作为胆固醇吸收抑制剂用于治疗高脂血症的用途。 还描述了它们的制造方法和含有它们的药物组合物。
-
9.发明公开
公开(公告)号：EP1173205A1
公开(公告)日：2002-01-23
申请号：EP00928046.2
申请日：2000-04-19
申请人： AstraZeneca AB
CPC分类号： A61K45/06 , A61K9/5026 , A61K9/5047 , A61K9/5078 , A61K31/00 , A61K31/554
摘要： An oral pharmaceutical formulation comprising an inhibitor compound of the ileal bile acid transport (IBAT inhibitor compound) and a therapeutically acceptable carrier characterised in that the formulation is designed to deliver the IBAT inhibitor compound in the ileum. The IBAT inhibitor compound can also be administered in combination with a bile acid binder to alleviate possible side effects of therapy with IBAT inhibitor compound, such as for instance diarrhoea. The bile acid binder may be formulated for colon release.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.019 秒)
